Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research Network.

Author information

Affiliations

  • 1. Epidemiology & Cancer Statistics Group, Department of Health Sciences, Centre for Blood Research, University of York, York, UK.
      Authors
    • Smith A 1
    • Frobisher C 1
    • Crouch S 1
    • Howell D 1
    • Roman E 1
    (5 authors)
  • 2. Department of Haematology, Leeds Cancer Centre, St James's University Hospital, Leeds, UK.
      Authors
    • Varghese A 2
    • Cook G 2
    (2 authors)
  • 3. Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK.
      Authors
    • Rawstron A 3
    • Cargo C 3
    • Burton C 3
    • Tooze R 3
    (4 authors)
  • 4. Hull York Medical School, University of York, Centre for Blood Research, York, UK.
      Authors
    • Fielding A 4
    (1 author)
  • 5. Department of Infection, Hull University Teaching Hospitals NHS Trust, Hull, UK.
      Authors
    • Eastick K 5
    • Easom N 5
    • Lillie P 5
    (3 authors)
    • Show all (6)

ORCIDs linked to this article

Show all (7)

British Journal of Haematology, 11 Nov 2025,
https://doi.org/10.1111/bjh.70244 PMID: 41220109 

Abstract 

When the World Health Organization (WHO) declared the global COVID-19 pandemic, it was recognised that patients with haematological cancers would be more susceptible to severe disease. Set within a UK population of ~4 million (https://hmrn.org/), all patients diagnosed with haematological neoplasms 2005-2019 who were alive on 1 January 2020 were followed up until March 2023. For comparative purposes, a similar age- and sex-matched general population cohort was also constructed. COVID-19 deaths were classified using ICD-10 codes and a multiple cause of death analysis was undertaken using a competing risk approach. Deaths of 486/18 883 haematology patients were attributed to COVID-19, yielding a cumulative incidence of 2.59% (95% confidence interval [CI]: 2.37-2.82) that was significantly higher than that of the general population (1.65; 95% CI: 1.58-1.72). In both cohorts, risks were higher in men, older people and those with co-morbidities. Within the patient cohort, excess mortality was largely concentrated in those suffering from more indolent conditions. Patients with the premalignancy MBL suffered from the highest excess mortality in the early phase of the pandemic when, unlike patients with malignancies, they were not advised to shield. Effects of shielding were evident and a clear vaccination benefit was demonstrated, with the exception of CLL and MCL; findings that warrant consideration in relation to other viruses.

Full text links 

Read article at publisher's site: https://doi.org/10.1111/bjh.70244

References 

Citations & impact 

This article has not been cited yet.

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

    Funding 

    Funders who supported this work.

    Blood Cancer UK

      Cancer Research UK (1)

      National Institute for Health and Care Research (1)

      • Grant ID: NIHR203331

        Loading publications

      • Annotations
        In abstract (12)
      • Save
      • Claim to ORCID